IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1167/iovs.08-2077 on May 30, 2008
 (Investigative Ophthalmology and Visual Science. 2008;49:4263-4268.)
© 2008 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.08-2077
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
iovs.08-2077v1
49/10/4263    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Bhattacharjee, P. S.
Right arrow Articles by Hill, J. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhattacharjee, P. S.
Right arrow Articles by Hill, J. M.

Effective Treatment of Ocular HSK with a Human Apolipoprotein E Mimetic Peptide in a Mouse Eye Model

Partha S. Bhattacharjee,1 Donna M. Neumann,1 Timothy P. Foster,2 Christian Clement,1 Gyanendra Singh,1 Hilary W. Thompson,1,3,4 Herbert E. Kaufman,1,2,3,5 and James M. Hill1,2,3,5

1From the Departments of Ophthalmology, 2Microbiology, Immunology, and Parasitology, and 5Pharmacology, the 3Neuroscience Center, and the 4Section of Biostatistics, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana.

PURPOSE. To evaluate efficacy of the small apolipoprotein E (apoE) mimetic dimer peptide (apoEdp) in the treatment of herpetic stromal keratitis in a mouse ocular model and determine its therapeutic effects against HSV-1–induced inflammatory cytokines.

METHODS. Female C57Bl/6 mice were corneally infected with HSV-1 strain KOS-GFP; topical treatment was initiated 24 hours after infection and continued for 10 consecutive days. Treatment groups were 1% apoEdp, 1% trifluorothymidine (TFT), and phosphate-buffered saline (PBS). The incidence and severity of stromal keratitis were monitored by slit lamp examination in a masked fashion. Infectious HSV-1 titer in eye swabs and alteration in inflammatory cytokines were determined in the early postinfection period by real-time RT-PCR.

RESULTS. One percent apoEdp treatment, which significantly reduced the incidence and severity of HSK, was equal to the effect of 1% TFT; both groups had significantly lower incidence and severity than the placebo treatment group. The in vivo mouse ocular model results of apoEdp therapy correlated with accelerated clearance of virus from eye swabs. Topical 1% apoEdp treatment in mice significantly downregulated gene expression of mouse proinflammatory cytokines.

CONCLUSIONS. These results suggest that topical treatment with apoE peptide has efficacy against HSK through anti-HSV-1 and anti-inflammatory activities.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Association for Research in Vision and Ophthalmology